Mon panier

HLA-A*0201 & B2M & HBV (FLLTRILTI)

HLA-A*0201 & B2M & HBV (FLLTRILTI) Liste de produits

  • Attribut

    Protein (2)

  • Bibliothèque de produits

    En ligne (2)

  • Espèces

    Human (2)

  • Étiquette

    His Tag & Avi Tag (2)

  • Marqueur

    Biotin-labeled (1)PE Labeled (1)

Numéro de produitEspècesSystème d'expressionDescription du produitStructure protéiquePuretéCaractéristiquesPré-commande/Commande
HLT-H82E9
Human
HEK293
Biotinylated Human HLA-A*02:01&B2M&HBV (FLLTRILTI) Complex Protein (Monomer, MALS verified) Ajouter au panier
HLV-HP2E4
Human
HEK293
PE-Labeled Human HLA-A*02:01&B2M&HBV (FLLTRILTI) Tetramer Protein Ajouter au panier
Quantité totale2
  • 1

HLA-A*0201 & B2M & HBV (FLLTRILTI)Contexte de la molécule

Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). The hepatitis B virus attacks the liver and can cause both acute and chronic diseases that put people at high risk of death from cirrhosis and liver cancer. The virus is most commonly transmitted from mother to child during birth and delivery, as well as through contact with blood or other body fluids. Hepatitis B virus (HBV) is a member of the hepadnaviral family. The virus particle (virion) consists of an outer lipid envelope and an icosahedral nucleocapsid core composed of the core protein. The nucleocapsid encloses the viral DNA and a DNA polymerase that has reverse transcriptase activity. The outer envelope contains embedded proteins that are involved in viral binding of, and entry into, susceptible cells. The surface antigens (HBsAg) decorating the lipid envelope of HBV are produced in excess during the life cycle of the virus, and its presence in blood indicates current hepatitis B infection. The Human HLA-A*0201 HBV ( FLLTRILTI) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M, and FLLTRILTI peptide of the HBV.

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
GRN Gene Therapy(Eli Lilly And Company)PR-006Phase 2 ClinicalEli Lilly And CompanyFrontotemporal Dementia
Details
TAK-594DNL-593; PTV:PGRN; TAK-594Phase 2 ClinicalDenali Therapeutics IncFrontotemporal Dementia
Details
AVB-101AVB-101Phase 2 ClinicalAviadoBio LtdFrontotemporal Dementia
Details
AL-101GSK-4527226; AL-101Phase 2 ClinicalAlector IncNerve Degeneration; Alzheimer Disease; Parkinson Disease; Frontotemporal Dementia; Amyotrophic Lateral Sclerosis
Details
PBFT-02PBFT-02Phase 2 ClinicalPassage Bio IncFrontotemporal Dementia
Details
AG-01(A&G Pharm)AG-01(A&G Pharm)Phase 1 ClinicalA&G PharmaceuticalTriple Negative Breast Neoplasms; Mesothelioma; Carcinoma, Non-Small-Cell Lung
Details
  • Liste de produits
  • Informations sur les médicaments cliniques